Skip to main content
Midas Edge

INTELLIGENT BIO SOLUTIONS INC

For the period ended Jun 30, 2024. Filed Sep 18, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Sep 18, 2024

INBS$2.29+16.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

Convertible preferred stock · Common stock · Treasury stock · Additional paid in · Accumulated · Other comprehensive · Non- controlling · Total shareholders’
Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · income · interest · equity
Balance, June 30, 2022*-$-62,042$620-$-$38,588,290$(31,175,853)$(788,135)$(79,151)$6,545,771
Reverse stock split rounding adjustment--9389--(9)----
Issuance of Series C preferred stock and common stock for acquisition, net of issuance costs2,363,00323,63012,347124--4,700,516---4,724,270
Issuance of Series D preferred stock, net of issuance costs176,4621,765----160,695---162,460
Stock awards issued to employees--2,08421--259,979---260,000
Payment of tax withholding for employee stock awards----(116)(1)(14,406)---(14,407)
Issuance of common stock and warrants, net of issuance costs--54,583546--2,093,121---2,093,667
Issuance of common stock upon cashless exercise of warrants--16,099161--(161)----
Conversion of convertible notes payable into Series C preferred stock1,149,27411,493----355,660---367,153
Conversion of convertible preferred shares into common stock(3,688,739)(36,888)46,107461--36,427----
Foreign currency translation income--------212,639-212,639
Net loss-------(10,631,720)-(32,835)(10,664,555)
Balance, June 30, 2023--194,2001,942(116)(1)46,180,112(41,807,573)(575,496)(111,986)3,686,998
Issuance of common stock, Series E Preferred Stock and warrants, net of issuance costs5,728,72357,287186,0181,860--3,727,017---3,786,164
Conversion of convertible preferred shares into common stock(5,728,723)(57,287)477,3944,774--52,513----
Conversion of holdback Series C Preferred Stock into common stock--6,24862--32,700---32,762
Issuance of common stock upon cashless exercise Series F warrants--655,0866,551--(6,122)---429
Reverse stock split rounding adjustment--47,501475--(475)----
Issuance of common stock upon cash exercise of Series E warrants--629,4096,291--1,645,207---1,651,498
Issuance of restricted stock to vendors--47,889479--216,342---216,821
Issuance of common stock, Series I, H1 and H2 warrants, net of issuance costs--675,1836,752--9,110,829---9,117,581
Issuance of common stock upon exercise of Pre-funded warrants--531,3105,313------5,313
Stock awards issued to employees--5,76258--13,617---13,675
Foreign currency translation loss--------(137,118)-(137,118)
Net loss-------(10,156,759)-(34,173)(10,190,932)
Balance, June 30, 2024--3,456,00034,557(116)(1)60,971,740(51,964,332)(712,614)(146,159)8,183,191
*Common Stock has been retroactively adjusted to reflect the decreased number of shares resulting from the 1-for-12 Reverse Stock Split on January 26, 2024, throughout the consolidated financial statements unless otherwise stated.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.